Mileutis, an Israel-based biopharmaceutical company, announced on Tuesday that it has added Bret Kossman and Ori Inbar as new executives to its board of directors.
Presently, Kossman is the managing director and head of Research and Analysis for Bank of America Merrill Lynch's Global Credit and Special Situations Group. He has served as the head of Japan Corporate Principal Investments and head of Asia Distressed Trading for Merrill Lynch, where he headed investments in private and public equity, mezzanine, and distressed debt. He has served as an investment banker at Salomon Smith Barney/Citigroup in New York and Tokyo where he worked on various capital raising and M&A transactions.
Inbar has more than 30 years of experience in the dairy industry and is presently an independent entrepreneur, investor, and consultant in agricultural technologies. He has more than 18 years of experience at Inbar where he has served as senior executive in SCR Dairy (currently owned by Merck & Co.). During his 18 years at SCR, he has held the position of senior executive and vice-president for Marketing, Sales, and Product Management.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study